Medicine guide

LUCENTIS

As listed in the register: LUCENTIS 10 MG/ML SOLUCION INYECTABLE EN JERINGA PRECARGADA

10 MG/ML · solución inyectable

  • Prescription only
  • Eyes and ears
Active substance
Ranibizumab
Made by
Novartis Europharm Limited

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

Medicine groupEyes and earsS01LA04

Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet

How it works

From the US prescribing label for the same active substance (LUCENTIS). It describes the substance, not this exact product.

Ranibizumab binds to the receptor binding site of active forms of VEGF-A, including the biologically active, cleaved form of this molecule, VEGF 110.

VEGF-A has been shown to cause neovascularization and leakage in models of ocular angiogenesis and vascular occlusion and is thought to contribute to pathophysiology of neovascular AMD, mCNV, DR, DME and macular edema following RVO.

Peak level after1 day
Half-life9 days
Mostly cleared after≈ 6 weeksfive half-lives — our arithmetic
PeakHalf gone6 weeks0
The shape is a standard model drawn from the two times above, not a measurement. How fast a medicine acts and wears off also depends on the dose, the form and the person.

Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-11-21

Safety of the active substance

From the US prescribing label for the same active substance (LUCENTIS). It describes the substance, not this exact product.

Must not be used by
  • Ocular or periocular infections ( 4.1 ) Hypersensitivity ( 4.2 ) 4.1 Ocular or Periocular Infections LUCENTIS is contraindicated in patients with ocular or periocular infections. 4.2 Hypersensitivity LUCENTIS is contraindicated in patients with known hypersensitivity to ranibizumab or any of the excipients in LUCENTIS.
  • Hypersensitivity reactions may manifest as severe intraocular inflammation.

Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

European UnionNo exact match for this strength and form

CanadaNo exact match for this strength and form

SwitzerlandNo exact match for this strength and form

Details

Made byNovartis Europharm Limited
Active substanceRanibizumab
Used inEyes and ears
Strength10 MG/ML
Formsolución inyectable
ClassificationS01LA04 · Eyes and ears
Routevía intravítrea
MarketedYes, according to the register
DrivingThe regulator flags that this medicine can affect the ability to drive.
Name in the registerLUCENTIS 10 MG/ML SOLUCION INYECTABLE EN JERINGA PRECARGADA
Nº Registro106374003

Source: CIMA — Centro de Información online de Medicamentos · 2026-09-30 · not reviewed by a clinician

Fuente: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA. Reuse terms: Aviso legal AEMPS.

Other strengths and forms

3 products are sold under this name. Grouped by form; a number on a strength means several companies make it.

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.